A detailed history of Sofinnova Investments, Inc. transactions in Ideaya Biosciences, Inc. stock. As of the latest transaction made, Sofinnova Investments, Inc. holds 1,749,455 shares of IDYA stock, worth $48.6 Million. This represents 5.24% of its overall portfolio holdings.

Number of Shares
1,749,455
Previous 1,151,528 51.92%
Holding current value
$48.6 Million
Previous $40.4 Million 37.08%
% of portfolio
5.24%
Previous 2.24%

Shares

10 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 13, 2024

BUY
$30.37 - $43.05 $18.2 Million - $25.7 Million
597,927 Added 51.92%
1,749,455 $55.4 Million
Q2 2024

Aug 09, 2024

BUY
$34.37 - $43.46 $12.7 Million - $16.1 Million
369,932 Added 47.33%
1,151,528 $40.4 Million
Q1 2024

Aug 14, 2024

SELL
$34.2 - $47.13 $12.7 Million - $17.4 Million
-369,932 Reduced 32.13%
781,596 $34.3 Million
Q1 2024

May 15, 2024

SELL
$34.2 - $47.13 $23.2 Million - $31.9 Million
-677,285 Reduced 46.42%
781,596 $34.3 Million
Q4 2023

Aug 15, 2024

BUY
$24.59 - $35.83 $7.56 Million - $11 Million
307,353 Added 26.69%
1,458,881 $51.9 Million
Q4 2023

Feb 12, 2024

BUY
$24.59 - $35.83 $19.5 Million - $28.5 Million
794,135 Added 119.46%
1,458,881 $51.9 Million
Q2 2023

Aug 14, 2023

BUY
$13.33 - $25.53 $2.82 Million - $5.4 Million
211,597 Added 46.69%
664,746 $15.6 Million
Q1 2023

May 11, 2023

SELL
$13.49 - $18.72 $288,429 - $400,252
-21,381 Reduced 4.51%
453,149 $6.22 Million
Q4 2022

Feb 13, 2023

SELL
$14.47 - $18.17 $2.61 Million - $3.27 Million
-180,226 Reduced 27.53%
474,530 $8.62 Million
Q3 2022

Nov 08, 2022

BUY
$9.24 - $15.79 $6.05 Million - $10.3 Million
654,756 New
654,756 $9.77 Million

Others Institutions Holding IDYA

About IDEAYA Biosciences, Inc.


  • Ticker IDYA
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 48,067,700
  • Market Cap $1.33B
  • Description
  • IDEAYA Biosciences, Inc., a synthetic lethality-focused precision medicine oncology company, focuses on the discovery and development of targeted therapeutics for patient populations selected using molecular diagnostics. The company's lead product candidates include IDE397, a methionine adenosyltransferase 2a inhibitor that is in Phase I clinica...
More about IDYA
Track This Portfolio

Track Sofinnova Investments, Inc. Portfolio

Follow Sofinnova Investments, Inc. and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Sofinnova Investments, Inc., based on Form 13F filings with the SEC.

News

Stay updated on Sofinnova Investments, Inc. with notifications on news.